Bortezomib-Mediated Up-Regulation of TRAIL-R1 and TRAIL-R2 Is Not Necessary for but Contributes to Sensitization of Primary Human Glioma Cells to TRAIL
Open Access
- 1 November 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (21), 6541-6542
- https://doi.org/10.1158/1078-0432.ccr-07-1759
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced ApoptosisClinical Cancer Research, 2007
- TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic windowHepatology, 2007
- Upregulation of TRAIL-R2 is not involved in HDACi mediated sensitization to TRAIL-induced apoptosisCell Death & Differentiation, 2006
- Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAILHepatology, 2005
- TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activationApoptosis, 2005
- Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM)Oncogene, 2004
- Persistent c-FLIP(L) Expression Is Necessary and Sufficient to Maintain Resistance to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand–Mediated Apoptosis in Prostate CancerCancer Research, 2004
- Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugsCell Death & Differentiation, 2004
- The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIPBlood, 2003
- Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosisOncogene, 2000